Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

KODBullishCorporate Developmentsnews

High materiality8/10

Kodiak's DAYBREAK topline could shift wet AMD prospects

Sep 25, 2026, 6:24 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Topline results for two Phase 3 retina programs constitute a material catalyst; strong data could re-rate odds of BLA readiness and drive near-term upside, similar to other biotech topline events that prompted outsized moves.

AI summary

What happened, with direct paths to the underlying reporting

Kodiak will announce DAYBREAK topline results for Zenkuda and KSI-501 on Sep 28, 2026. Positive toplines could accelerate regulatory momentum and lift sentiment for two late-stage retinal programs targeting the $15 billion anti-VEGF market. Investors will watch how results shape BLA readiness and set expectations for December 2026 PEAK data and 2Q 2027 PINNACLE timing.

Kodiak to report DAYBREAK Phase 3 topline results on Sept 28, 2026.
Results cover Zenkuda and KSI-501 for wet AMD in a 2-program readout.
Zenkuda and KSI-501 target the $15B anti-VEGF retinal market.
PEAK topline data expected Dec 2026; PINNACLE in 2Q2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.